Integrated BioPharma, Inc. (INBP)
OTCMKTS
· Delayed Price · Currency is USD
0.300
0.00 (0.00%)
Mar 5, 2026, 9:30 AM EST
Integrated BioPharma Income Statement
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Revenue | 52.09 | 54.35 | 50.32 | 50.67 | 56.25 | 63.56 | Upgrade
|
| Revenue Growth (YoY) | -0.06% | 8.02% | -0.70% | -9.91% | -11.51% | 20.45% | Upgrade
|
| Cost of Revenue | 48.02 | 48.79 | 46.43 | 46.61 | 49.69 | 54.08 | Upgrade
|
| Gross Profit | 4.07 | 5.56 | 3.88 | 4.06 | 6.55 | 9.48 | Upgrade
|
| Selling, General & Admin | 3.49 | 3.54 | 3.63 | 3.94 | 3.81 | 3.7 | Upgrade
|
| Operating Expenses | 3.49 | 3.54 | 3.63 | 3.94 | 3.81 | 3.7 | Upgrade
|
| Operating Income | 0.58 | 2.02 | 0.25 | 0.12 | 2.75 | 5.78 | Upgrade
|
| Interest Expense | -0.05 | -0.05 | -0.05 | -0.01 | -0.13 | -0.26 | Upgrade
|
| Interest & Investment Income | 0.13 | 0.09 | 0.07 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0 | 0 | -0 | -0.01 | 0.01 | 0.06 | Upgrade
|
| EBT Excluding Unusual Items | 0.67 | 2.06 | 0.27 | 0.1 | 2.63 | 5.59 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | -0.06 | 0 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | 0.02 | - | Upgrade
|
| Asset Writedown | 0.03 | - | - | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | - | 1.66 | Upgrade
|
| Pretax Income | 0.7 | 2.06 | 0.27 | 0.1 | 2.6 | 7.25 | Upgrade
|
| Income Tax Expense | 0.9 | 1.25 | 0.16 | 0.13 | -1.24 | -0.77 | Upgrade
|
| Net Income | -0.21 | 0.81 | 0.11 | -0.03 | 3.84 | 8.01 | Upgrade
|
| Net Income to Common | -0.21 | 0.81 | 0.11 | -0.03 | 3.84 | 8.01 | Upgrade
|
| Net Income Growth | - | 621.43% | - | - | -52.10% | 95.06% | Upgrade
|
| Shares Outstanding (Basic) | 31 | 30 | 30 | 30 | 30 | 30 | Upgrade
|
| Shares Outstanding (Diluted) | 31 | 31 | 31 | 30 | 32 | 32 | Upgrade
|
| Shares Change (YoY) | -1.62% | 0.95% | 3.08% | -7.34% | 0.65% | 3.07% | Upgrade
|
| EPS (Basic) | -0.01 | 0.03 | 0.00 | -0.00 | 0.13 | 0.27 | Upgrade
|
| EPS (Diluted) | -0.01 | 0.03 | 0.00 | -0.00 | 0.12 | 0.25 | Upgrade
|
| EPS Growth | - | 635.32% | - | - | -52.00% | 92.31% | Upgrade
|
| Free Cash Flow | 2.82 | 1.87 | 0.39 | 1.12 | 3.61 | 2.76 | Upgrade
|
| Free Cash Flow Per Share | 0.09 | 0.06 | 0.01 | 0.04 | 0.11 | 0.09 | Upgrade
|
| Gross Margin | 7.81% | 10.23% | 7.72% | 8.01% | 11.65% | 14.92% | Upgrade
|
| Operating Margin | 1.11% | 3.72% | 0.50% | 0.24% | 4.88% | 9.10% | Upgrade
|
| Profit Margin | -0.40% | 1.49% | 0.22% | -0.07% | 6.82% | 12.61% | Upgrade
|
| Free Cash Flow Margin | 5.42% | 3.45% | 0.78% | 2.20% | 6.41% | 4.33% | Upgrade
|
| EBITDA | 0.88 | 2.34 | 0.56 | 0.47 | 3.08 | 6.12 | Upgrade
|
| EBITDA Margin | 1.69% | 4.30% | 1.11% | 0.93% | 5.48% | 9.63% | Upgrade
|
| D&A For EBITDA | 0.31 | 0.32 | 0.31 | 0.35 | 0.34 | 0.34 | Upgrade
|
| EBIT | 0.58 | 2.02 | 0.25 | 0.12 | 2.75 | 5.78 | Upgrade
|
| EBIT Margin | 1.11% | 3.72% | 0.50% | 0.24% | 4.88% | 9.10% | Upgrade
|
| Effective Tax Rate | 129.64% | 60.81% | 58.21% | 134.00% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.